Correlation Between Bristol Myers and Aligos Therapeutics

Can any of the company-specific risk be diversified away by investing in both Bristol Myers and Aligos Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol Myers and Aligos Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Bristol Myers Squibb and Aligos Therapeutics, you can compare the effects of market volatilities on Bristol Myers and Aligos Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol Myers with a short position of Aligos Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol Myers and Aligos Therapeutics.

Diversification Opportunities for Bristol Myers and Aligos Therapeutics

-0.33

Correlation Coefficient

Bristol Myers  Aligos Therapeutics

Very good diversification

The 3 months correlation between Bristol and Aligos is -0.33. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and Aligos Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Aligos Therapeutics and Bristol Myers is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with Aligos Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Aligos Therapeutics has no effect on the direction of Bristol Myers i.e., Bristol Myers and Aligos Therapeutics go up and down completely randomly.

Pair Corralation between Bristol Myers and Aligos Therapeutics

Considering the 90-day investment horizon Bristol Myers Squibb is expected to generate 0.21 times more return on investment than Aligos Therapeutics. However, Bristol Myers Squibb is 4.68 times less risky than Aligos Therapeutics. It trades about 0.01 of its potential returns per unit of risk. Aligos Therapeutics is currently generating about -0.06 per unit of risk. If you would invest  5,929  in Bristol Myers Squibb on December 2, 2024 and sell it today you would earn a total of  33.00  from holding Bristol Myers Squibb or generate 0.56% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Bristol Myers Squibb  vs.  Aligos Therapeutics

Bristol Myers Squibb

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong primary indicators, Bristol Myers is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Aligos Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Aligos Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Bristol Myers and Aligos Therapeutics

The main advantage of trading using opposite Bristol Myers and Aligos Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol Myers position performs unexpectedly, Aligos Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aligos Therapeutics will offset losses from the drop in Aligos Therapeutics' long position.

The idea behind Bristol Myers Squibb and Aligos Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.